GamaMabs Pharma Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $2.08M

  • Investors
  • 9

GamaMabs Pharma General Information

Description

Developer of optimized therapeutic antibodies designed for the treatment of cancer. The company's monoclonal antibodies have increased tumor cell-killing properties which target anti-mullerian human receptors in ovarian cancer, thereby enabling physicians to treat unaddressed specific targets in gynecological cancers.

Contact Information

Website
www.gamamabs.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Centre Pierre Potier, Oncopole entrée B
  • 1 place Pierre Potier BP50624
  • 31106 Toulouse
  • France
+33 01 00 00 00 00
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Centre Pierre Potier, Oncopole entrée B
  • 1 place Pierre Potier BP50624
  • 31106 Toulouse
  • France
+33 01 00 00 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

GamaMabs Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Early Stage VC 13-Sep-2021 $2.08M 000.00 000.00 Completed Clinical Trials - Phase 1
5. Early Stage VC 16-Jul-2020 00.000 000.00 000.00 Completed Clinical Trials - Phase 1
4. Early Stage VC 20-Jun-2018 00.000 000.00 000.00 Completed Clinical Trials - Phase 1
3. Early Stage VC (Series B) 15-Dec-2015 000.00 000.00 Completed Clinical Trials - Phase 1
2. Early Stage VC 03-Mar-2014 $1.5M $6.31M Completed Startup
1. Early Stage VC (Series A) 30-Sep-2013 $4.81M $4.81M 00.000 Completed Startup
To view GamaMabs Pharma’s complete valuation and funding history, request access »

GamaMabs Pharma Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Shares C 00,000 00.000000 000.00 000.00 00 000.00 00.00
Shares B 000,000 00.000000 0000.00 0000.00 00 0000.00 00.00
Shares P 38,402 $2.357795 $110.52 $110.52 1x $110.52 13.35%
To view GamaMabs Pharma’s complete cap table history, request access »

GamaMabs Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of optimized therapeutic antibodies designed for the treatment of cancer. The company's monoclonal antibodies
Drug Discovery
Toulouse, France
7 As of 2021
000.00
000.00 0000-00-00
0000000000 0 000.00

000 00

la pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui o
0000 000000000
Barcelona, Spain
00 As of 0000
0000
00000000000 0000

000000

onsectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore
0000 000000000
Cambridge, MA
00 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

GamaMabs Pharma Competitors (13)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ona Therapeutics Venture Capital-Backed Barcelona, Spain 00 0000 00000000000 0000
Avalyn Pharma Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
Volastra Venture Capital-Backed New York, NY 00 00000 0000000000 0 00000
Lung Therapeutics Formerly VC-backed Austin, TX 00 000.00 000000&0 000.00
Loxo Oncology Formerly VC-backed Stamford, CT 00 00000 000000&0 00000
You’re viewing 5 of 13 competitors. Get the full list »

GamaMabs Pharma Patents

  • 20

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 14

    Granted

  • 1

    Pending

  • 000

    Expiring in next 12 mo

GamaMabs Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3812008-A1 Amh-competitive antagonist antibody Inactive 23-Oct-2019 00000000000 00
US-20230348607-A1 Amh-competitive antagonist antibody Pending 23-Oct-2019 00000000000
EP-3789401-A1 Amhrii-binding antibody drug conjugates and their use thereof in the treatment of cancers Inactive 03-Sep-2019 00000000000 00
US-20190367625-A1 Amhrii-binding compounds for preventing or treating cancers Inactive 14-Apr-2017 00000000000
JP-6987742-B2 Anti-human her3 antibody and its use Active 06-May-2015 A61P35/00
To view GamaMabs Pharma’s complete patent history, request access »

GamaMabs Pharma Executive Team (5)

Name Title Board Seat
Jean-Marc Barret Ph.D Head of Pharmacology & Pharmacology Manager
Thierry Hercend Ph.D Chairman
You’re viewing 2 of 5 executive team members. Get the full list »

GamaMabs Pharma Board Members (10)

Name Representing Role Since
Aneta Sottil Andera Partners Board Member 000 0000
François Thomas Ph.D Self Board Member 000 0000
Gilles Nobecourt Andera Partners Board Member 000 0000
Jean-Michel Petit Self Board Member 000 0000
Martine George MD Self Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

GamaMabs Pharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

GamaMabs Pharma Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Edmond de Rothschild Private Equity PE/Buyout Minority 000 0000 000000 0
Andera Partners PE/Buyout Minority 000 0000 000000 0
IRDI Capital Investissement Asset Manager Minority 000 0000 000000 0
Alto Invest Asset Manager Minority 000 0000 000000 0
Bpifrance Sovereign Wealth Fund Minority 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »

Ready to get started?

Request a free trial

GamaMabs Pharma FAQs

  • When was GamaMabs Pharma founded?

    GamaMabs Pharma was founded in 2013.

  • Where is GamaMabs Pharma headquartered?

    GamaMabs Pharma is headquartered in Toulouse, France.

  • What is the size of GamaMabs Pharma?

    GamaMabs Pharma has 7 total employees.

  • What industry is GamaMabs Pharma in?

    GamaMabs Pharma’s primary industry is Drug Discovery.

  • Is GamaMabs Pharma a private or public company?

    GamaMabs Pharma is a Private company.

  • What is the current valuation of GamaMabs Pharma?

    The current valuation of GamaMabs Pharma is 000.00.

  • What is GamaMabs Pharma’s current revenue?

    The current revenue for GamaMabs Pharma is 000000.

  • How much funding has GamaMabs Pharma raised over time?

    GamaMabs Pharma has raised $31.5M.

  • Who are GamaMabs Pharma’s investors?

    Edmond de Rothschild Private Equity, Andera Partners, IRDI Capital Investissement, Alto Invest, and Bpifrance are 5 of 9 investors who have invested in GamaMabs Pharma.

  • Who are GamaMabs Pharma’s competitors?

    Ona Therapeutics, Avalyn Pharma, Volastra, Lung Therapeutics, and Loxo Oncology are some of the 13 competitors of GamaMabs Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »